Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc (RPTX) is a clinical-stage biotechnology company pioneering precision oncology therapies through its synthetic lethality platform and CRISPR-enabled target discovery. This page aggregates official announcements, research breakthroughs, and strategic developments critical for understanding the company's progress in developing targeted cancer treatments.
Investors and researchers will find comprehensive updates on clinical trial milestones, regulatory filings, and scientific collaborations. The curated news collection includes updates on therapeutic candidates, partnership agreements, and peer-reviewed research findings, providing a centralized hub for tracking RPTX's contributions to oncology innovation.
Key content areas cover clinical-stage developments, research publications, and strategic partnerships that demonstrate the company's scientific rigor. All materials are sourced from verified corporate communications and reputable industry publications to ensure reliability.
Bookmark this page for streamlined access to Repare Therapeutics' latest advancements in CRISPR-based drug discovery and precision oncology solutions. Check back regularly for real-time insights into their mission to develop therapies targeting genetic vulnerabilities in cancer cells.
Repare Therapeutics Inc. (NASDAQ: RPTX) has announced a proposed underwritten public offering of $75 million in common shares, with a 30-day underwriters' option for an additional $11.25 million. The offering is subject to market conditions, and the exact terms are yet to be finalized. The shares will be sold by Repare, which has previously filed a registration statement with the SEC. Morgan Stanley, Goldman Sachs, Cowen, and Piper Sandler are acting as joint book-running managers for this offering.
Repare Therapeutics, a precision oncology company, announced participation in a fireside chat at H.C. Wainwright's 2nd Annual Precision Oncology Conference on October 20, 2021, at 12:30 p.m. ET. Investors can access a live webcast via their website, with an archived replay available for 90 days. Repare focuses on synthetic lethality for cancer therapies, utilizing their CRISPR-enabled SNIPRx® platform. Their product pipeline includes RP-3500, an ATR inhibitor in Phase 1/2 development, RP-6306, a PKMYT1 inhibitor in Phase 1, and other early-stage programs.
Repare Therapeutics (RPTX) has presented preliminary Phase 1 clinical data for RP-3500 at the AACR-NCI-EORTC conference, indicating positive early efficacy in patients with solid tumors having specific genomic alterations. Out of 101 patients, the drug showed a favorable safety profile, with only 21.8% experiencing grade 3 anemia and no major adverse events leading to discontinuation. The recommended Phase 2 dose was established at 160mg weekly. Promising antitumor activity was noted, with 49% of patients showing clinical benefit, paving the way for further development of RP-3500.
Repare Therapeutics Inc. (NASDAQ: RPTX) announced an inadvertent early issuance of an abstract by the ANE Conference regarding initial clinical data from its Phase 1/2 trial of RP-3500. The presentation, scheduled for October 8, 2021, will feature significantly more patient data than the abstract. Repare will host a virtual investor webcast on the same day to discuss the updated findings. The company specializes in precision oncology using its SNIPRx® platform to develop targeted cancer therapies, including RP-3500 and others currently in development.
Repare Therapeutics Inc. (RPTX) announced key presentations at the AACR-NCI-EORTC Virtual International Conference on October 8, 2021. Initial data from the ongoing Phase 1/2 trial of RP-3500, an ATR inhibitor targeting advanced solid tumors, will be presented. Dr. Timothy Yap will discuss the biomarker-driven trial results during an oral session, while additional preclinical data will be showcased through a poster presentation. A virtual investor webcast is also scheduled for the same day, allowing insights into the promising trial data.
Repare Therapeutics (NASDAQ: RPTX) has appointed Thomas Civik as Chairman of the Board, succeeding Jerel Davis, who remains on the Board. Civik brings over 25 years of experience in the pharma and biotech sectors, including leading roles at Five Prime Therapeutics and Foundation Medicine. His expertise in oncology drug development will be vital as Repare advances its clinical pipeline with candidates RP-3500 and RP-6306. This leadership change is seen as a strategic move to bolster the company's growth and innovation in precision oncology.
Repare Therapeutics Inc. (NASDAQ: RPTX), a clinical-stage precision oncology company, will participate in a fireside chat at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on September 9 at 2:45 p.m. ET. The event will highlight the company's proprietary synthetic lethality approach in cancer therapy development, particularly through its SNIPRx® platform. Repare's pipeline includes key products such as RP-3500, an ATR inhibitor in Phase 1/2 trials, and RP-6306, a PKMYT1 inhibitor in Phase 1 trials. A live webcast of the chat will be available on the company's website.
Repare Therapeutics Inc. (RPTX) reported its Q2 financial results, highlighting significant advancements in clinical trials. The company successfully dosed the first patient in the Phase 1b/2 ATTACC trial of its ATR inhibitor RP-3500, aimed at treating molecularly selected cancers. Cash and marketable securities stood at $301 million. However, net losses increased to $26.3 million, or $0.71 per share, compared to $11.8 million, or $2.45 per share, in the same period last year, largely due to rising R&D and G&A expenses.
Repare Therapeutics Inc. (Nasdaq:RPTX), a clinical-stage precision oncology company, announced its senior management's participation in a fireside chat at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference on June 9 at 3:50 p.m. ET. The live webcast can be accessed via the Company’s website, with an archived replay available for 30 days. Repare focuses on synthetic lethality for developing targeted cancer therapies, including its lead candidate RP-3500, an ATR inhibitor in Phase 1/2 development. For more details, visit reparerx.com.
Repare Therapeutics Inc. (RPTX) reported its Q1 2021 financial results, highlighting progress in clinical trials and pipeline advancements. The Company’s ATR inhibitor RP-3500 is in Phase 1/2 development, with initial results expected in H2 2021. The Phase 1 trial of RP-6306 is underway, with the first patient dosed ahead of schedule. As of March 31, 2021, cash equivalents totaled $319.1 million. Net R&D expenses rose to $16.5 million, reflecting increased development costs, while G&A expenses reached $5.2 million. The net loss for the quarter was $21.4 million, or $0.58 per share.
